Citations

Clear

3138 citation(s) found for "Smith, AM".

Psychophysiologic Factors and Performance in Ice Hockey Goalies During Competition
Smith, AM, Finnie, SB, Stuart, MJ, Meis, J, Beaver, KM , Laskowski, ER, Wf, Young

Mayo Clinic

Journal of ASTM International | May 26, 2004 | Volume: 1 | Issue: 2 | Pages: 1-17

10.1520/jai11305 Get It

Abstract Studying goalies, who play a key position in hockey requires examining psychophysiologic variables and their relationship to performance during games when the outcome is important [15]. This investigation tested all three aspects of emotion (subjective, physiologic changes, and performance). Nine male goalies completed questionnaires and provided salivary cortisol before, during, and after each game. Heart rate (ECG signal) was integrated with the goalie's performance video. Goalies rated on Likert Scales; headaches, stomach aches, insomnia, nervousness, and awareness of heart pounding. Data from 16 games were obtained. Of nine, two goalies provided data on three games each; one goalie was classified as a responder and the other a non-responder, based on salivary cortisol levels (SCL). The responder's SCL increased 572 % between baseline and post-period assessments, whereas SCL in the non-responder increased 50 % above baseline. The responder's SCL increased eight times baseline when he faced 16 shots in a period. The responder goalie's game heart rates (HRs) were 160, 152, and 167 beats per minute (bpm) and the non-responder's HRs were 147, 132, and 142 bpm for three games. Game performance was similar for both goalies.
The Power of the Denominator: A Proposal for More Comprehensive Modeling of Risk Factors in Ice Hockey Injuries
Stuart, MJ, Smith, AM, Larson, DR

Mayo Clinic

Journal of ASTM International | May 26, 2004 | Volume: 1 | Issue: 2 | Pages: 1-6

10.1520/jai11293 Get It

Abstract In the sport of ice hockey, the incidence of injury has been investigated at multiple levels of participation based on collective player exposure, which assumes equal playing time among participants. However, playing time varies enormously between individual players on a given team because of variability in the number and length of shifts. Individual player monitoring, although laborintensive, more accurately identifies risk factors for sustaining injuries. Specific player exposure data are necessary for detailed analysis of factors such as style of play, illegal activities, equipment, player size, and officiating. In addition, prospective, uniform and accurate collection of exposure data may permit meaningful comparison of injury rates between levels of participation in ice hockey and also among different sports. Refinement of data collection tools that determine individual player injury exposure will increase the power of the denominator and facilitate prevention of ice hockey injuries.
Intimidation in Ice Hockey: An Exploratory Assessment
Crawford, BJ, Stuart, MJ, Smith, AM, Brennan, RD

Mayo Clinic

Journal of ASTM International | May 26, 2004 | Volume: 1 | Issue: 2 | Pages: 1-12

10.1520/jai11291 Get It

Abstract The purpose of this investigation was to examine the components of intimidation in ice hockey and to determine their effects on players, coaches, and referees. In a pilot test, hockey coaches (N = 17) from three levels of participation were invited to an informal, exploratory symposium to assess their opinions on the role of intimidation in ice hockey. The following themes emerged: a) coaches' behavior and expectations, b) observable behavior, c) player's perceived role, and d) sociological factors. A preliminary intimidation model was developed. A survey including 80 open-ended questionnaires designed to stimulate discussion on the definition of intimidation, methods used to intimidate, and factors perceived as intimidating, was distributed to players (N = 66), coaches (N = 8), and referees (N = 6). The data were analyzed using qualitative methods [1,2] and intimidation was defined. Results support a theoretical model, which serves as a point of departure for future research and visually depicts the components of intimidation and their interactions.
The Heat Shock Protein 70 Cochaperone Hip Enhances Functional Maturation of Glucocorticoid Receptor
Nelson, Gregory M. , Prapapanich, Viravan, Carrigan, Patricia E., Roberts, Patricia J., Smith, David F. , Riggs, Daniel L.

Mayo Clinic

Molecular Endocrinology | April 13, 2004 | Volume: 18 | Issue: 7 | Pages: 1620-1630

10.1210/me.2004-0054 | PMID 15071092 Get It

Pilot Study of Idarubicin-Based Intensive-Timing Induction Therapy for Children With Previously Untreated Acute Myeloid Leukemia: Children's Cancer Group Study 2941
Lange, Beverly J., Dinndorf, Patricia A., Smith, Franklin O. , Arndt, Carola, Barnard, Dorothy, Feig, Stephen A. , Feusner, James H., Seibel, Nita L. , Weiman, Margie, Aplenc, Richard , Gerbing, Robert B., Alonzo, Todd A.

Mayo Clinic

Journal of Clinical Oncology | December 30, 2003 | Volume: 22 | Issue: 1 | Pages: 150-156

10.1200/jco.2004.04.016 | PMID 14701777 Get It

Purpose Randomized comparisons of idarubicin (IDA) with daunorubicin (DNR) show that in adults with acute myeloid leukemia (AML), IDA achieves higher remission rates and longer remission durations. In Children's Cancer Group Pilot Study CCG-2941, we assessed toxicity and feasibility of substituting 4 mg of DNR with 1 mg of IDA in intensive-timing daunorubicin-based induction therapy (DNR/DNR) used in CCG-2891. Patients and Methods On days 1 through 3 and 10 through 14, patients received two courses of dexamethasone, cytarabine, 6-thioguanine, etoposide, and IDA (IDA/IDA). After enrollment of 65 patients, toxicity prompted replacement of IDA with DNR (IDA/DNR) on days 10 through 14 for the remaining 28 patients. Outcomes were compared with those of intensive timing in CCG-2891. Results Treatment-related mortality after two courses of induction was not significantly different among the three regimens: 14% with IDA/IDA, 7% with IDA/DNR, and 9% with DNR/DNR. In course 1 of CCG-2941 IDA/IDA, 11% of patients withdrew compared with 1.5% in CCG-2891 (P < .001) and 5% in CCG-2941 IDA/DNR (P = not significant). Compared with CCG-2891 DNR/DRN, CCG-2941 IDA/IDA increased days in hospital (43 v 36 days; P = .007), mean duration of course 1 by a week (P = .002), and risk of grade 3 or 4 hyperbilirubinemia (18% v 5%; P = .02). Toxicity of IDA/DNR was not different from that of DNR/DNR in CCG-2891. The mean day 7 marrow blast percentage was 11.4% in CCG-2941 versus 21.1% in CCG-2891 (P = .004). Remission induction, survival, and event-free survival rates were not significantly different from those of CCG-2891. Conclusion In CCG-2941, excessive toxicity and withdrawals outweighed potential benefits of early response with IDA.
Current Perspective on the Pathogenesis of Graves’ Disease and Ophthalmopathy
Bahn, Rebecca S. , Smith, Terry J. , Prabhakar, Bellur S.

Mayo Clinic

Endocrine Reviews | December 11, 2003 | Volume: 24 | Issue: 6 | Pages: 802-835

10.1210/er.2002-0020 | PMID 14671007 Get It

Adenovirus-Mediated Gene Transfer to Human Cerebral Arteries
Khurana, Vini G., Weiler, Deborah A., Springett, Margaret J., Parisi, Joseph E. , Meyer, Fredric B. , Marsh, W. Richard , Katušić, Zvonimir S. , Smith, Leslie , O’Brien, Timothy

Mayo Clinic

Journal of Cerebral Blood Flow & Metabolism | November 18, 2003 | Volume: 20 | Issue: 9 | Pages: 1360-1371

10.1097/00004647-200009000-00011 | PMID 10994858 Get It

Gene therapy is being investigated as a putative treatment option for cardiovascular diseases, including cerebral vasospasm. Because there is presently no information regarding gene transfer to human cerebral arteries, the principal objective of this study was to characterize adenovirus-mediated expression and function of recombinant endothelial nitric oxide synthase (eNOS) gene in human pial arteries. Pial arteries (outer diameter 500 to 1000 μm) were isolated from 30 patients undergoing temporal lobectomy for intractable seizures and were studied using histologic staining, histochemistry, electron microscopy, and isometric force recording. Gene transfer experiments were performed ex vivo using adenoviral vectors encoding genes for bovine eNOS (AdCMVeNOS) and Escherichia coli β-galactosidase (AdCMVLacZ). In transduced arteries, studied 24 hours after exposure to vectors, expression of recombinant β-galactosidase and eNOS was detected by histochemistry, localizing mainly to the adventitia (n = 4). Immunoelectron microscopy localized recombinant eNOS in adventitial fibroblasts. During contractions to U46619, bradykinin-induced relaxations were significantly augmented in AdCMVeNOS-transduced rings compared with control and AdCMVLacZ-transduced rings ( P < 0.01; n = 6). The NOS inhibitor L-nitroarginine methylester (L-NAME) caused significantly greater contraction in AdCMVeNOS-transduced rings ( P < 0.001; n = 4) and inhibited bradykinin-induced relaxations in control and transduced rings ( P < 0.001; n = 6). The current findings suggest that in AdCMVeNOS-transduced human pial arteries, expression of recombinant eNOS occurs mainly in adventitial fibroblasts where it augments relaxations to NO-dependent agonists such as bradykinin. Findings from the current study might be beneficial in future clinical applications of gene therapy for the treatment or prevention of cerebral vasospasm.
Evaluation of the TRUGENE HCV 5 ′ NC Genotyping Kit with the New GeneLibrarian Module 3.1.2 for Genotyping of Hepatitis C Virus from Clinical Specimens
Germer, Jeffrey J., Rosser, Michael, Thompson, Amber , Mitchell, P. Shawn, Smith, Thomas F., Elagin, Slava, Yao, Joseph D. , Majewski, David

Mayo Clinic

Journal of Clinical Microbiology | October 7, 2003 | Volume: 41 | Issue: 10 | Pages: 4855-4857

10.1128/jcm.41.10.4855-4857.2003 | PMID 14532242 Get It

ABSTRACT The TRUGENE HCV 5′NC genotyping kit (GeneLibrarian modules 3.1.1 and 3.1.2) and VERSANT HCV genotyping assay were compared by using 96 hepatitis C virus (HCV) RNA-positive patient specimens, including HCV genotypes 1, 2, 3, 4, 5, 6, and 10. The TRUGENE HCV 5 ′ NC genotyping kit (GeneLibrarian module 3.1.2) yielded the most accurate genotyping results.
American College of Cardiology/American Heart Association Clinical Practice Guidelines: Part II
Gibbons, Raymond J. , Smith, Sidney C. , Antman, Elliott M.

Mayo Clinic

Circulation | June 23, 2003 | Volume: 107 | Issue: 24 | Pages: 3101-3107

10.1161/01.cir.0000079017.53579.9c | PMID 12821590 Get It